Previous close | 3.5000 |
Open | 3.5000 |
Bid | 0.0000 |
Ask | 3.2000 |
Strike | 165.00 |
Expiry date | 2025-06-20 |
Day's range | 3.5000 - 3.5000 |
Contract range | N/A |
Volume | |
Open interest | 9 |
A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Key Insights Amgen's estimated fair value is US$537 based on 2 Stage Free Cash Flow to Equity Amgen's US$309 share...